Agios Pharmaceuticals Share Price Today
(NASDAQ: AGIO)

Name: Agios Pharmaceuticals Share Price Today (NASDAQ: AGIO) - Agios Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Agios Pharmaceuticals share price is $33.12 & ₹2,893.61 as on 4 Mar 2025, 2.30 'hrs' IST

$33.12

▲

-2.42

(-6.81%)

Market is closed - opens 8 PM, 04 Mar 2025

View live Agios Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Agios Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Agios Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Agios Pharmaceuticals share price movements

Today's Low: $32.82
Today's High: $35.70
$33.12
0.91%
Downside
Day's Volatility :8.07%
Upside
7.23%
52 Weeks Low: $27.14
52 Weeks High: $62.58
$33.12
18.06%
Downside
52 Weeks Volatility :56.63%
Upside
47.08%

Agios Pharmaceuticals (AGIO) Returns

Period	Agios Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-43.75%	1.9%	0.0%
6 Months	-25.96%	-4.5%	0.0%
1 Year	2.95%	2.4%	0.0%
3 Years	7.08%	12.9%	-11.6%

Agios Pharmaceuticals (AGIO) Key Statistics

in dollars & INR

Previous Close	$35.54
Open	$35.55
Today's High	$35.701
Today's Low	$32.82
Market Capitalization	$2.0B
Today's Volume	$976.7K
52 Week High	$62.58
52 Week Low	$27.14
Revenue TTM	$36.5M
EBITDA	$-420.1M
Earnings Per Share (EPS)	$11.64
PE Ratio	3.05
Profit Margin	1845.92%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	57.29%

How to invest in Agios Pharmaceuticals Stock (AGIO) from India?

It is very easy for Indian residents to invest directly in Agios Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Agios Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Agios Pharmaceuticals or AGIO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Agios Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Agios Pharmaceuticals shares which would translate to 0.026 fractional shares of Agios Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Agios Pharmaceuticals, in just a few clicks!

Returns in Agios Pharmaceuticals (AGIO) for Indian investors in Rupees

The Agios Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Agios Pharmaceuticals investment value today

Current value as on today

₹1,08,374

Returns

₹8,374

(+8.37%)

Returns from Agios Pharmaceuticals Stock

₹2,953 (+2.95%)

Dollar Returns

₹5,421 (+5.42%)

Indian investors sentiment towards Agios Pharmaceuticals (AGIO)

-33%

Period: Feb 1, 2025 to Mar 3, 2025. Change in 30 Days versus previous period

Search interest for Agios Pharmaceuticals Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Agios Pharmaceuticals

Farallon Capital Management, L.L.C.
9.90%
Vanguard Group Inc
9.83%
BlackRock Inc
8.76%
Bellevue Group AG
6.14%
T. Rowe Price Associates, Inc.
4.23%
Armistice Capital, LLC
3.95%

Analyst Recommendation on Agios Pharmaceuticals

Buy

73%Buy

26%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Agios Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Agios Pharmaceuticals Stock (AGIO)

What analysts predicted

Upside of 67.57%

Target:

$55.50

Current:

$33.12

Insights on Agios Pharmaceuticals Stock (Ticker Symbol: AGIO)

Price Movement
In the last 3 months, AGIO stock has moved down by -44.3%
Increasing Revenue
Revenue is up for the last 5 quarters, 7.10M → 10.73M (in $), with an average increase of 9.6% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 947.91M → -96.52M (in $), with an average decrease of 110.2% per quarter
AGIO vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 59.3%
AGIO vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 48.1% return, outperforming this stock by 43.1%
Price to Sales
ForAGIO every $1 of sales, investors are willing to pay $51.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

AGIO Agios Pharmaceuticals Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$117.9M	↑ 24.92%
Net Income	$-396.6M	↑ 14.62%
Net Profit Margin	-336.36%	↑ 30.25%

	FY20	Y/Y Change
Revenue	$203.2M	↑ 72.33%
Net Income	$-335.2M	↓ 15.48%
Net Profit Margin	-164.97%	↑ 171.39%

	FY21	Y/Y Change
Revenue	$41.4K	↓ 99.98%
Net Income	$1.6B	↓ 578.71%
Net Profit Margin	3.9M%	↑ 3875445.71%

	FY22	Y/Y Change
Revenue	$14.2M	↑ 34288.66%
Net Income	$-74.6M	↓ 104.65%
Net Profit Margin	-523.56%	↓ 3875804.3%

	FY23	Y/Y Change
Revenue	$26.8M	↑ 88.36%
Net Income	$-352.1M	↑ 372.25%
Net Profit Margin	-1.3K%	↓ 789.07%

	FY24	Y/Y Change
Revenue	$36.5M	↑ 36.07%
Net Income	$673.7M	↓ 291.35%
Net Profit Margin	1.8K%	↑ 3158.55%

	Q3 FY23	Q/Q Change
Revenue	$7.4M	↑ 10.24%
Net Income	$-91.3M	↑ 8.97%
Net Profit Margin	-1.2K%	↑ 14.33%

	Q4 FY23	Q/Q Change
Revenue	$7.1M	↓ 4.0%
Net Income	$-95.9M	↑ 5.05%
Net Profit Margin	-1.4K%	↓ 116.43%

	Q1 FY24	Q/Q Change
Revenue	$8.2M	↑ 15.29%
Net Income	$-81.5M	↓ 15.0%
Net Profit Margin	-995.84%	↑ 354.86%

	Q2 FY24	Q/Q Change
Revenue	$8.6M	↑ 5.2%
Net Income	$-96.1M	↑ 17.87%
Net Profit Margin	-1.1K%	↓ 119.87%

	Q3 FY24	Q/Q Change
Revenue	$9.0M	↑ 4.05%
Net Income	$947.9M	↓ 1086.2%
Net Profit Margin	10.6K%	↑ 11690.4%

	Q4 FY24	Q/Q Change
Revenue	$10.7M	↑ 19.7%
Net Income	$-96.5M	↓ 110.18%
Net Profit Margin	-899.56%	↓ 11474.25%

	FY19	Y/Y Change
Profit	$116.6M	↑ 25.38%

	FY20	Y/Y Change
Profit	$200.4M	↑ 71.87%

	FY21	Y/Y Change
Profit	$-18.8M	↓ 109.37%

	FY22	Y/Y Change
Profit	$12.5M	↓ 166.76%

	FY23	Y/Y Change
Profit	$17.3M	↑ 38.15%

	FY24	Y/Y Change
Profit	$32.3M	↑ 86.69%

	Q3 FY23	Q/Q Change
Profit	$6.8M	↑ 20.74%

	Q4 FY23	Q/Q Change
Profit	$5.1M	↓ 24.42%

	Q1 FY24	Q/Q Change
Profit	$6.2M	↑ 21.51%

	Q2 FY24	Q/Q Change
Profit	$5.5M	↓ 11.06%

	Q3 FY24	Q/Q Change
Profit	$8.2M	↑ 48.02%

	Q4 FY24	Q/Q Change
Profit	$9.5M	↑ 15.76%

	FY19	Y/Y Change
Operating Cash Flow	$-370.6M	↑ 21.75%
Investing Cash Flow	$91.4M	↓ 133.39%
Financing Cash Flow	$289.6M	↓ 46.96%

	FY20	Y/Y Change
Operating Cash Flow	$-290.8M	↓ 21.55%
Investing Cash Flow	$75.7M	↓ 17.16%
Financing Cash Flow	$261.5M	↓ 9.7%

	FY21	Y/Y Change
Operating Cash Flow	$-407.3M	↑ 40.09%
Investing Cash Flow	$1.2B	↑ 1548.64%
Financing Cash Flow	$-765.8M	↓ 392.82%

	FY22	Y/Y Change
Operating Cash Flow	$-309.5M	↓ 24.02%
Investing Cash Flow	$243.3M	↓ 80.52%
Financing Cash Flow	$2.4M	↓ 100.31%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-61.6M	↓ 7.65%
Investing Cash Flow	$39.3M	↓ 16.52%
Financing Cash Flow	$1.9M	↑ 694.09%

Agios Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Agios Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Agios Pharmaceuticals (AGIO) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Agios Pharmaceuticals, Inc.	-1.47%	-25.96%	2.95%	7.08%	-31.85%
Regeneron Pharmaceuticals, Inc.	2.7%	-41.4%	-29.48%	10.71%	40.29%
Beone Medicines Ltd	9.92%	30.42%	46.27%	36.61%	57.72%
Vertex Pharmaceuticals Incorporated	2.75%	1.6%	13.98%	105.19%	103.66%
Alnylam Pharmaceuticals, Inc.	-11.3%	-4.04%	62.31%	49.4%	108.31%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Agios Pharmaceuticals, Inc.	3.05	3.05	0.0	-7.19	0.57	-0.2	NA	26.96
Regeneron Pharmaceuticals, Inc.	18.22	18.22	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Agios Pharmaceuticals, Inc.	Buy	$2.0B	-31.85%	3.05	1845.92%
Regeneron Pharmaceuticals, Inc.	Buy	$76.4B	40.29%	18.22	31.07%
Beone Medicines Ltd	NA	$28.0B	57.72%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$123.2B	103.66%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.9B	108.31%	NA	-12.37%

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Organization	Agios Pharmaceuticals
Employees	486
CEO	Mr. Brian M. Goff M.B.A.
Industry	Health Technology

Management People of Agios Pharmaceuticals

Name	Title
Mr. Brian M. Goff M.B.A.	CEO & Director
Ms. Cecilia Jones	Chief Financial Officer
Mr. James William Burns	Corporate Secretary & Chief Legal Officer
Dr. Sarah Gheuens M.D., Ph.D.	Chief Medical Officer and Head of Research & Development
Ms. Tsveta Milanova	Chief Commercial Officer
Mr. T. J. Washburn	VP, Controller & Principal Accounting Officer
Dr. Clive Patience Ph.D.	Chief Technical Operations Officer
Mr. Christopher J. M. Taylor	Vice President of Investor Relations & Corporate Communications
Mr. Steven Vickers	Vice President of Sales
Ms. Ellen LoPrestiv	Chief People Officer

Important FAQs about investing in AGIO Stock from India :

What is Agios Pharmaceuticals share price today?

Agios Pharmaceuticals share price today stands at $33.12, Open: $35.55 ; Previous Close: $35.54 ; High: $35.70 ; Low: $32.82 ; 52 Week High: $62.58 ; 52 Week Low: $27.14.

The stock opens at $35.55, after a previous close of $35.54. The stock reached a daily high of $35.70 and a low of $32.82, with a 52-week high of $62.58 and a 52-week low of $27.14.

Can Indians buy Agios Pharmaceuticals shares?

Yes, Indians can invest in the Agios Pharmaceuticals (AGIO) from India.

With INDmoney, you can buy Agios Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Agios Pharmaceuticals at zero transaction cost.

How can I buy Agios Pharmaceuticals shares from India?

It is very easy to buy Agios Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Agios Pharmaceuticals (AGIO) be purchased?

Yes, you can buy fractional shares of Agios Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Agios Pharmaceuticals stocks?

To start investing in Agios Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.